行情

OMER

OMER

奥麦罗制药
NASDAQ

实时行情|Nasdaq Last Sale

13.55
-0.15
-1.09%
盘后: 13.55 0 0.00% 16:00 01/24 EST
开盘
13.77
昨收
13.70
最高
13.87
最低
13.53
成交量
21.42万
成交额
--
52周最高
20.92
52周最低
12.52
市值
7.31亿
市盈率(TTM)
-8.4439
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

OMER 新闻

  • Omeros seeks accelerated approval from FDA for new drug
  • American City Business Journals.3天前
  • Ocular Therapeutix: Executing On Dextenza's Launch, A Name To Own In 2020
  • Seeking Alpha - Article.2019/12/30 13:06
  • Hedge Funds Aren’t Crazy About Omeros Corporation (OMER) Anymore
  • Insider Monkey.2019/12/20 22:16
  • myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab
  • Business Wire.2019/12/18 13:30

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

OMER 简况

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.
展开

Webull提供Omeros Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。